MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Danaher Corp

Suletud

SektorTervishoid

196.46 -0.12

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

192.46

Max

196.82

Põhinäitajad

By Trading Economics

Sissetulek

268M

1.1B

Müük

738M

6.5B

P/E

Sektori keskmine

34.964

57.333

Aktsiakasum

2.14

Dividenditootlus

0.69

Kasumimarginaal

16.611

Töötajad

61,000

EBITDA

-230M

1.4B

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+22.75% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.69%

2.63%

Järgmine tulemuste avaldamine

22. juuli 2025

Järgmine dividendimakse kuupäev

25. apr 2025

Turustatistika

By TradingEconomics

Turukapital

-29B

134B

Eelmine avamishind

196.58

Eelmine sulgemishind

196.46

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Danaher Corp Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

22. apr 2025, 10:34 UTC

Tulu

Danaher 1Q Results Decline But Top Estimates

5. veebr 2025, 12:54 UTC

Tulu

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29. jaan 2025, 11:44 UTC

Tulu

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22. okt 2024, 10:35 UTC

Tulu

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

22. apr 2025, 10:02 UTC

Tulu

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22. apr 2025, 10:02 UTC

Tulu

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22. apr 2025, 10:02 UTC

Tulu

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22. apr 2025, 10:01 UTC

Tulu

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22. apr 2025, 10:01 UTC

Tulu

Danaher 1Q Adjusted Core Revenue Flat >DHR

22. apr 2025, 10:00 UTC

Tulu

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22. apr 2025, 10:00 UTC

Tulu

Danaher 1Q Adj EPS $1.88 >DHR

22. apr 2025, 10:00 UTC

Tulu

Danaher 1Q EPS $1.32 >DHR

22. apr 2025, 10:00 UTC

Tulu

Danaher 1Q Sales $5.74B >DHR

22. apr 2025, 10:00 UTC

Tulu

Danaher 1Q Net $954M >DHR

29. jaan 2025, 15:25 UTC

Market Talk
Tulu

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29. jaan 2025, 13:56 UTC

Peamised uudised
Tulu

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29. jaan 2025, 11:08 UTC

Tulu

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29. jaan 2025, 11:07 UTC

Tulu

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29. jaan 2025, 11:07 UTC

Tulu

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29. jaan 2025, 11:02 UTC

Tulu

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29. jaan 2025, 11:01 UTC

Tulu

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29. jaan 2025, 11:01 UTC

Tulu

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Cont Ops EPS $1.49 >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Net $1.09B >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q EPS $1.49 >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Adj EPS $2.14 >DHR

29. jaan 2025, 11:00 UTC

Tulu

Danaher 4Q Sales $6.5B >DHR

22. okt 2024, 10:02 UTC

Tulu

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22. okt 2024, 10:02 UTC

Tulu

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Võrdlus sarnastega

Hinnamuutus

Danaher Corp Prognoos

Hinnasiht

By TipRanks

22.75% tõus

12 kuu keskmine prognoos

Keskmine 241.2 USD  22.75%

Kõrge 265 USD

Madal 210 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Danaher Corp 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

15

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

190.1 / 205.11Toetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Bullish Evidence

Pikk perspektiiv

Weak Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.